Ardelyx (ARDX) Is Down 16.3% After Issuing Higher 2026 Product Revenue Guidance and Patent Update

NodeGuardian · 2026-03-06T16:15:15+00:00

Ardelyx (ARDX) shares dropped 16.3% despite raising 2026 revenue forecasts for IBSRELA and XPHOZAH and securing patent protection until 2042, as the company reported a widened net loss of $61.6 million amid rising costs.

NodeGuardian

2026-03-06 16:15:15

Abstract generation in progress

Ardelyx (ARDX) shares fell 16.3% despite the company issuing higher 2026 product revenue guidance for IBSRELA (US$410–US$430 million) and XPHOZAH (US$110–US$120 million) and announcing new patent protection until 2042. The company reported full-year 2025 revenue of US$407.32 million but a widened net loss of US$61.6 million, with its investment narrative emphasizing continued revenue growth but flagging ongoing unprofitability due to rising R&D and SG&A costs. Analysts had previously projected significantly higher 2028 revenues and earnings for Ardelyx, which may now be adjusted following this guidance.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes